



# Test Definition: MYCON

Mycoplasma pneumoniae Antibody Interpretation

## Overview

### Useful For

Interpretation for *Mycoplasma pneumoniae* screening results

### Method Name

Only orderable as part of a profile. For more information see MYCO / *Mycoplasma pneumoniae* Antibodies, IgG and IgM, Serum.

Technical Interpretation

### NY State Available

Yes

## Specimen

### Specimen Type

Serum

### Specimen Required

Only orderable as part of a profile. For more information see MYCO / *Mycoplasma pneumoniae* Antibodies, IgG and IgM, Serum.

### Reject Due To

### Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Serum	Refrigerated (preferred)	14 days	
	Frozen	14 days	

## Clinical & Interpretive

### Clinical Information

*Mycoplasma pneumoniae* is a small bacterium transmitted via organism-containing droplets. It is a cause of upper respiratory infection, pharyngitis, and tracheobronchitis, particularly in children, and has been associated with approximately 20% of cases of community-acquired pneumonia. Central nervous system and cardiac manifestations are probably the most frequent extrapulmonary complications of infections due to *M pneumoniae*. The disease is usually self-limited, although severe disease has been reported in immunocompromised patients.

Identification of *M pneumoniae* by culture-based methods is time consuming and insensitive. Serology-based assays for *M pneumoniae* have several drawbacks. The development of IgM antibodies takes approximately 1 week, and the IgM response may be variable in adults or decreased in immunosuppressed individuals. Confirmation of the disease is dependent on the observation of a 4-fold rise in IgG antibody titers between acute and convalescent specimens, several weeks following the initial onset of illness, providing clinical utility only for retrospective testing. Real-time polymerase chain reaction analysis offers a rapid and sensitive option for detection of *M pneumoniae* DNA from clinical specimens allows for diagnosis of acute or current infection.

## Reference Values

Only orderable as part of a profile. For more information see MYCO / *Mycoplasma pneumoniae* Antibodies, IgG and IgM, Serum.

Negative

## Interpretation

IgG ELISA result	IgM ELISA result	Interpretation
Positive	Negative	Results suggest past exposure.
Positive	Reactive	Prior exposure to <i>Mycoplasma pneumoniae</i> detected. Confirmatory testing for IgM to <i>M pneumoniae</i> will be performed by an immunofluorescence assay.
	Equivocal	
Negative	Negative	No antibodies to <i>M pneumoniae</i> detected. Acute infection cannot be ruled out as antibody levels may be below the limit of detection. If clinically indicated, a second serum should be submitted in 14 to 21 days.
Negative	Reactive	No prior exposure to <i>Mycoplasma pneumoniae</i> . Confirmatory testing for IgM to <i>M pneumoniae</i> will be performed by an immunofluorescence assay.
	Equivocal	
Equivocal	Negative	Recommend follow-up testing in 10 to 14 days if clinically indicated.
Equivocal	Reactive	Confirmatory testing for IgM to <i>M pneumoniae</i> will be performed by an immunofluorescence assay.
	Equivocal	

ELISA = Enzyme-linked immunosorbent assay

## Cautions

A diagnosis of *Mycoplasma pneumoniae* infection should not be solely based on results of serologic testing for this agent. Test results should be interpreted in conjunction with clinical evaluation and the results of other diagnostic procedures (eg, molecular detection).

The continued presence or absence of antibodies cannot be used to determine the success or failure of therapy.

Testing should not be performed as a screening procedure for the general population. Testing should only be done when clinical evidence suggests the diagnosis of *M pneumoniae*-associated disease.

The performance of this test has not been established on neonates and immunocompromised patients.

Performance of the IgM assay has not been tested with specimens known to be positive for antibodies to organisms that are known to be associated with lower respiratory illness (ie, influenza A and B, cytomegalovirus, *Chlamydophila pneumoniae*, parainfluenza), and closely related serovars known to cross-react with *M pneumoniae*, such as *Mycoplasma genitalium* and *Mycoplasma hominis*, as well as various *Ureaplasma* species. Cross-reactivity studies with such organisms have not been performed with this assay.

The IgG removal system included with the IgM test system has been shown to functionally remove the IgG from specimens containing total IgG levels ranging from 300 to 600 mg/mL. The effectiveness of this removal system at IgG levels exceeding 600 mg/mL has not been established.

### Clinical Reference

1. Smith T: *Mycoplasma pneumoniae* infections: diagnosis based on immunofluorescence titer of IgG and IgM antibodies. Mayo Clin Proc 1986;61(10):830-831
2. Holzman RS, Simberkoff MS, Leaf HL: *Mycoplasma pneumoniae* and atypical pneumonia. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:2332-2339

## Performance

### Method Description

Automated interpretation of IgM and IgG antibody results for *Mycoplasma pneumoniae*.

### PDF Report

No

### Day(s) Performed

Monday through Friday

### Report Available

Same day/1 to 3 days

### Performing Laboratory Location

Mayo Clinic Laboratories - Rochester Superior Drive

## Fees & Codes

### Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.

- 
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

Not Applicable

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
MYCON	M. pneumoniae Ab Interpretation	In Process

Result ID	Test Result Name	Result LOINC® Value
MYCON	M. pneumoniae Ab Interpretation	69048-7